Rosneft Studying Morgan Stanley Oil Trading Unit

Russian state-run oil company Rosneft is in talks with Morgan Stanley on buying into the Wall Street bank's oil trading business, an industry publication and two industry sources said on Tuesday.

Morgan Stanley has been trying to sell or spin off its physical commodity business for over a year as it faces increased regulatory pressure and higher capital requirements. Rosneft is Russia's top oil producer and is headed by Igor Sechin, a powerful ally of Russian President Vladimir Putin. The Russian state owns a 69.5% stake, according to its website.

"There have been some talks between Morgan and Rosneft. There is no deal," said a source familiar with the situation. A second senior trading source said people close to the situation had briefed him that such talks had taken place. Industry publication SparkSpread, which tracks people moves in commodities trading, cited an unidentified source as saying the talks were at an advanced stage but could still fall apart. A Morgan Stanley spokesman in New York and a Rosneft spokesman in Moscow declined to comment.

Market participants have listed Qatar and Chinese investors among the potential buyers for the assets, which include major storage tanks and pipelines in the United States. Morgan Stanley is the biggest physical oil trader on Wall Street, and its commodity arm owns TransMontaigne Inc, an oil storage and terminal firm with assets in the United States and Mexico.

The Federal Reserve has been reviewing Wall Street's role in physical commodity trading and is considering placing greater restrictions on the ownership and operation of trading assets. The review comes as politicians have increasingly accused banks of pursuing activities that add to market volatility. U.S. regulators may also be concerned that a major problem such as an oil spill could expose banks seen as too big to fail to unnecessary risks.

Rosneft became the world's biggest listed oil producer in March after the $55 billion acquisition of Anglo-Russian oil firm TNK-BP. Its oil output accounts for over 40% of the total in Russia, the global leader in crude production. Rosneft has amassed assets abroad in the past few years, including refineries in Germany and Italy, but has bought no significant assets in the United States. Rosneft has an oil trading division in Geneva, which helps supply its refining assets in Europe.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.